News

We launched Similis to make a wider selection of biosimilars available to patients, and we look forward to working...

The agreement assigns rights to four biosimilar programs across a broad range of indications to Blau for commercialization.

Newly launched business line leverages the combined experience and technical knowledge of leaders in analytical, cell-line, and process development to reduce up-front time and resource costs for biosimilar developers.